← Back to headlines
Exagen Reports Record Revenue Growth Amidst Ongoing Losses
Exagen (XGN) remains a focus for investors due to its record revenue growth and higher test pricing, despite the company continuing to report losses.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
